AstraZeneca's Lynparza gets European approval to treat BRCA-mutated ovarian cancer

December 19, 2014 6:56 PM

4 0

AstraZeneca has received approval from the European Commission (EC) for Lynparza (olaparib) capsules 400mg twice daily as the first therapy to treat adults with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The drug is approved for patients who are in complete response or partial response to platinum-based chemotherapy.

Read more

To category page